SCHEMBL4079804

SCHEMBL4079804

CC(C)C[SiH](CC(C)C)c1ccc(COC2CCCCO2)cc1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ICAM1 P05362 1/20 0.38
SELE P16581 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CREBBP Q92793 2/20 0.35
KDM4C Q9H3R0 1/20 0.34
EP300 Q09472 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.32
TACR1 P25103 3/20 0.32
P2RX3 P56373 4/20 0.32
CARM1 Q86X55 1/20 0.30
PRMT6 Q96LA8 1/20 0.30
NFE2L2 Q16236 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4077026 0.87 KDM4C (0.43) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL4072891 0.85 MEN1 (0.38) ICAM1SELEMEN1KMT2ACREBBP
SCHEMBL14229857 0.79 ICAM1 (0.38) ICAM1SELEMEN1KMT2ACREBBP
SCHEMBL12141797 0.79 ICAM1 (0.42) ICAM1SELEMEN1KMT2ACREBBP
SCHEMBL14065905 0.79 ICAM1 (0.42) ICAM1SELEMEN1KMT2ACREBBP
SCHEMBL22859636 0.78 ICAM1 (0.39) ICAM1SELEMEN1KMT2ACREBBP
SCHEMBL14228857 0.78 ICAM1 (0.39) ICAM1SELEMEN1KMT2ACREBBP
SCHEMBL4317051 0.77 ICAM1 (0.45) ICAM1SELEMEN1KMT2ACREBBP
SCHEMBL4081854 0.76 ICAM1 (0.40) ICAM1SELEMEN1KMT2ACREBBP
SCHEMBL12139817 0.76 ALDH1A1 (0.41) ICAM1SELEMEN1KMT2ACREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074135-A2 SILICON DERIVATIVES FOR PET IMAGING Bayer Schering Pharma AG (DE) 2009-07-01 EP disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
EP-1970064-A1 Silicon-derivatives for pet-imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-17 EP disclosed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP disclosed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 WO disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 WO disclosed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP disclosed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035215-A1 RADIOFLUORINATION AFF2, AFF1, NUTF2 ICAM1 2963/4885SELE 3071/4885MEN1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.